Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.22.69 extracted from

  • Chen, Y.W.; Yiu, C.B.; Wong, K.Y.
    Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates (2020), F1000Res., 9, 129 .
    View publication on PubMed
Search for more literature for 3.4.22.69

Organism

Organism UniProt Comment Textmining
Severe acute respiratory syndrome coronavirus 2 MN908947 i.e. SARS-CoV-2
-

Synonyms

Synonyms Comment Organism
2019-nCoV 3C-like protease
-
 Severe acute respiratory syndrome coronavirus 2
3cLpro
-
 Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2 3C-like protease
-
 Severe acute respiratory syndrome coronavirus 2

General Information

General Information Comment Organism
drug target based on the near-identical substrate specificities and high sequence identities (between SARS-CoV-2 and SARS-CoV (86%)), some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart: the antivirals ledipasvir or velpatasvir, the drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) can be effective Severe acute respiratory syndrome coronavirus 2
additional information the overall amino-acid sequence identity of SARS-CoV-2 and SARS-CoV is very high (86%). The conservation is noticeable at the polyprotein cleavage sites. All 11 3CLpro sites are highly conserved or identical, inferring that their respective proteases have very similar specificities. The 3CLpro sequence of SARS-CoV-2 has only 12 out of 306 residues different from that of SARS-CoV (identity = 96%). Conserved sequence identity is detected among all 11 SARS-CoV-2 genomes SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2